Option Care Health
Delivers complex infusion therapies at home and in ambulatory suites.
Something off on this page? Send us feedback.
Profile
Delivers pharmaceuticals, compounded solutions, nursing, and clinical support for infusion therapies administered at home or in ambulatory suites. A single nationwide infusion-services segment earns revenue from goods and services delivered to patients, while relying on payer contracts, physician referrals, licensed clinical staff, and drug access.
Provides home and alternate-site infusion care across the United States through a single infusion-services segment. Its therapy portfolio spans anti-infectives, nutrition support, immunoglobulin, chronic inflammatory and neurological disorders, bleeding disorders, women's health, heart failure, and other specialized treatments.
Combines full-service pharmacies and ambulatory infusion suites with Naven Health's nationwide nursing network. Multidisciplinary teams dispense pharmaceuticals and complex compounded solutions, support administration, educate patients, and monitor therapy under physician-directed care plans. Referral channels include health systems, physicians, discharge planners, and managed-care organizations.
Revenue comes from pharmaceuticals and clinical services delivered to patients, with reimbursement governed by commercial and government payer arrangements. Operations depend on payer contracts and reimbursement benchmarks, pharmacy and clinician licensing, reliable drug supply, and manufacturer access for new therapies.
Company facts
Key statistics
Year to date −25.9% · Average volume (30d) 2.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Deutsche Bank | Downgrade | Buy | Hold | $26 | $24 |
| Jul 17, 2026 | Stephens | Target | $30 | $24 | ||
| Jul 17, 2026 | Stephens & Co. | Downgrade | Overweight | Equal Weight | ||
| Jun 8, 2026 | Goldman Sachs | Reiterate | Neutral | $27 | $22 | |
| May 6, 2026 | Morgan Stanley | Reiterate | Overweight | $35 | $28 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | $0.43 | $0.45 | +5.6% | $1.42B | $1.44B | +1.6% | +6.45% |
| Apr 30, 2026Q1 FY26 | $0.37 | $0.40 | +8.1% | $1.39B | $1.35B | −2.8% | −1.48% |
| Feb 24, 2026Q4 FY25 | $0.46 | $0.46 | 0.0% | $1.46B | $1.47B | +0.2% | −0.65% |
| Oct 30, 2025Q3 FY25 | $0.43 | $0.45 | +4.7% | $1.46B | $1.44B | −1.9% | −0.69% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.33B | $1.42B | $1.44B | $1.47B | $1.35B | $1.44B | |
| Gross profit | $247.3M | $252.8M | $256.6M | $263.6M | $247.1M | $267.3M | |
| Operating income | $79.2M | $82.7M | $84.5M | $91.5M | $77.2M | $85.1M | |
| Net income | $46.7M | $50.5M | $51.8M | $58.5M | $45.3M | $53.9M | |
| Diluted EPS | $0.28 | $0.31 | $0.32 | $0.37 | $0.29 | $0.35 | |
| Gross margin | 18.6% | 17.9% | 17.9% | 18.0% | 18.3% | 18.5% | |
| Operating margin | 5.9% | 5.8% | 5.9% | 6.2% | 5.7% | 5.9% |
Fiscal years (4-quarter sums)FY21 $3.44B · FY22 $3.94B · FY23 $4.30B · FY24 $5.00B · FY25 $5.65B
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $193.8M · Total debt $1.27B · Total assets $3.38B · Shareholders' equity $1.26B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 149.79M · Float 138.67M · 92.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 22.10M | 14.76% | 13F | Aug 7, 2026 |
| Wellington Management Group LLP | 11.78M | 7.87% | 13F | Aug 14, 2026 |
| Wellington Investment Advisors Holdings LLP | 9.92M | 5.80% | 13G | Nov 8, 2024 |
| Vanguard Portfolio Management LLC | 8.27M | 5.52% | 13F | Aug 13, 2026 |
| Fuller & Thaler Asset Management, Inc. | 7.45M | 4.97% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 7, 2026 | Timothy P. Sullivan | director | +24,154 | $20.69 |
| May 4, 2026 | Harry M. Jansen Jr Kraemer | director | +36,610 | $21.41 |
| May 4, 2026 | John Charles Rademacher | director, officer: Chief Executive Officer | +12,500 | $21.18 |
| May 4, 2026 | Meenal Sethna | officer: Chief Financial Officer | +16,225 | $20.16 |
| Feb 27, 2026 | Michael Bavaro | officer: Chief Human Resources Officer | −6,000 | $33.00 |
Peers
- UnitedHealth Group
Payer-linked rival in infusion and specialty pharmacy
- CVS Health
Overlap in home infusion, specialty pharmacy, and PBM channels
- Cigna
Specialty pharmacy and PBM overlap in complex therapies
- BrightSpring Health Services
Direct home-infusion overlap through Amerita specialty infusion
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Option Care Health | $23.90 | 0.00% | $3.58B | 18.0 | 12.2 | 0.6 | +1.9% |
| UnitedHealth Group | $392.50 | −0.12% | $356.86B | 25.3 | 18.4 | 0.8 | +0.4% |
| CVS Health | $93.07 | +0.02% | $118.74B | 24.6 | 11.5 | 0.3 | +7.3% |
| Cigna | $279.20 | +0.06% | $73.69B | 11.5 | 8.8 | 0.3 | +6.6% |
| BrightSpring Health Services | $60.31 | +2.01% | $11.60B | 44.1 | 28.9 | 0.8 | +23.0% |
| Median | 24.9 | 14.9 | 0.5 | +6.9% |